Radius Health Appoints Former Novartis Executive Tony Rosenberg to Board of Directors | Previous Release
Radius Health Appoints Former Novartis Executive Tony Rosenberg to Board of Directors (NASDAQ:RDUS)
Radius Health Appoints Former Novartis Executive Tony Rosenberg to Board of Directors
WALTHAM, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today the appointment of Tony Rosenberg to its Board of Directors.
Mr. Rosenberg had a long and successful career at Novartis, most recently serving as Corporate Head of M&A and Licensing for all of Novartis.
He previously held various general management and executive leadership positions, including roles in business development, strategic planning, and marketing and sales.
"Our Board and management team are thrilled to have Tony become the newest member of the Board as we work together to guide and shape future success."
Tony Rosenberg will also be taking the role of Chair of the Strategy Committee, replacing Dr. Morana Jovan, who resigned from the Radius Board.
Tony Rosenberg first joined Sandoz in the UK in1980 where he held various leadership positions in sales and marketing, business development and strategic planning.
In 1994, he
moved to Basel, initially in international product marketing, and after undertaking roles of increasing responsibility, he
was named Head Global Marketing Primary Care.
In 2000, Tony was named Global Head of the Transplant and Immunology Business Unit, and in 2005 he was appointed Global Head Business Development & Licensing (Pharma).
In this role, Tony
managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestitures, mergers, and acquisitions.
In 2013, he was appointed as Corporate Head of M&A and Licensing.
Most recently, Tony
was responsible for the Portfolio Transformation transactions undertaken by Novartis
Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.